Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis
Top Cited Papers
- 15 January 2019
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 321 (2), 156-164
- https://doi.org/10.1001/jama.2018.20046
Abstract
Question Can a short duration of fecal microbiota transplantation (FMT) using anaerobically prepared pooled stool suspension induce remission in active ulcerative colitis? Findings In this randomized clinical trial that included 73 adults with mild to moderately active ulcerative colitis, the proportion achieving steroid-free remission at 8 weeks was 32% with donor FMT vs 9% with autologous FMT, a significant difference. Meaning Anaerobically prepared fecal microbiota transplantation may be effective in treating ulcerative colitis, but further research is needed to assess longer-term efficacy and safety. Importance High-intensity, aerobically prepared fecal microbiota transplantation (FMT) has demonstrated efficacy in treating active ulcerative colitis (UC). FMT protocols involving anaerobic stool processing methods may enhance microbial viability and allow efficacy with a lower treatment intensity. Objective To assess the efficacy of a short duration of FMT therapy to induce remission in UC using anaerobically prepared stool. Design, Setting, and Participants A total of 73 adults with mild to moderately active UC were enrolled in a multicenter, randomized, double-blind clinical trial in 3 Australian tertiary referral centers between June 2013 and June 2016, with 12-month follow-up until June 2017. Interventions Patients were randomized to receive either anaerobically prepared pooled donor FMT (n = 38) or autologous FMT (n = 35) via colonoscopy followed by 2 enemas over 7 days. Open-label therapy was offered to autologous FMT participants at 8 weeks and they were followed up for 12 months. Main Outcomes and Measures The primary outcome was steroid-free remission of UC, defined as a total Mayo score of ≤2 with an endoscopic Mayo score of 1 or less at week 8. Total Mayo score ranges from 0 to 12 (0 = no disease and 12 = most severe disease). Steroid-free remission of UC was reassessed at 12 months. Secondary clinical outcomes included adverse events. Results Among 73 patients who were randomized (mean age, 39 years; women, 33 [45%]), 69 (95%) completed the trial. The primary outcome was achieved in 12 of the 38 participants (32%) receiving pooled donor FMT compared with 3 of the 35 (9%) receiving autologous FMT (difference, 23% [95% CI, 4%-42%]; odds ratio, 5.0 [95% CI, 1.2-20.1]; P = .03). Five of the 12 participants (42%) who achieved the primary end point at week 8 following donor FMT maintained remission at 12 months. There were 3 serious adverse events in the donor FMT group and 2 in the autologous FMT group. Conclusions and Relevance In this preliminary study of adults with mild to moderate UC, 1-week treatment with anaerobically prepared donor FMT compared with autologous FMT resulted in a higher likelihood of remission at 8 weeks. Further research is needed to assess longer-term maintenance of remission and safety. Trial Registration anzctr.org.au Identifier: ACTRN12613000236796Keywords
This publication has 26 references indexed in Scilit:
- Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled TrialGastroenterology, 2015
- Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative ColitisGastroenterology, 2015
- Fecal Microbiota Transplant for Clostridium difficile Colitis–Induced Toxic MegacolonThe American Journal of Gastroenterology, 2015
- Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infectionAlimentary Pharmacology & Therapeutics, 2015
- Systematic review with meta‐analysis: the declining risk of colorectal cancer in ulcerative colitisAlimentary Pharmacology & Therapeutics, 2014
- Duodenal Infusion of Donor Feces for RecurrentClostridium difficileThe New England Journal of Medicine, 2013
- Comparative effects of very low-carbohydrate, high-fat and high-carbohydrate, low-fat weight-loss diets on bowel habit and faecal short-chain fatty acids and bacterial populationsBritish Journal of Nutrition, 2009
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisThe New England Journal of Medicine, 2005
- A simple clinical colitis activity indexGut, 1998
- Cortisone in Ulcerative ColitisBMJ, 1955